Analysis Of Clinical Features And Prognosis Of Patients With Lung Adenocarcinoma Complicated With Metabolic Syndrome

Objectives To analyze the clinical features of patients with lung adenocarcinoma complicated with metabolic syndrome,and to explore the impact of metabolic syndrome on the quality of life and prognosis of patients with lung adenocarcinoma.Methods Collect and analyze a total of 286 patients with lung adenocarcinoma(all confirmed by pathological diagnosis)hospitalized in the Affiliated Hospital of North China University of Technology from January 2015 to June 2018,117 cases with metabolic syndrome were selected as the case group,and 169 cases without metabolic syndrome as the control group.The clinical data of patients were collected retrospectively,including gender,age,urban and rural origin,body mass index(BMI),smoking history,family history of tumor,blood pressure,fasting blood glucose,triglyceride(TG),high density lipoprotein(HDL-C),Low-density lipoprotein(LDL-C),clinical TNM staging,degree of differentiation,lymph node metastasis,quality of life score(EORTC QLQ-C30 V3.0),calculation of PFS(progressive survival)and OS(overall survival).Follow up and followup through outpatient service,telephone,etc.until June 2019.SPSS 20.0 software was used for data analysis and processing,measurement data was subjected to independent sample t test;count data was subjected to ?~2 test;multivariate analysis was performed using Logistic regression model.Kaplan-Meier method and COX model were used for survival analysis.The test levels were both bilateral,?=0.05.Results 1 The levels of BMI,hypertension,hyperglycemia,hyperlipidemia,triglycerides,high-density lipoprotein,and low-density lipoprotein between the case group and the control group were statistically significant(all P<0.05),while age,gender,urban and rural origin,smoking history,Family history of tumor,clinical TNM stage,degree of differentiation,lymph node metastasis,and treatment of lung adenocarcinoma,there was no difference between the two groups(all P>0.05).2 The single factor analysis of the quality of life score found that the body function,emotional function,cognitive function,social function and overall health score were significantly lower in the case group than the control group,and the pain symptom score in the case group was higher than the control group(all P<0.05)After multi-factor analysis of the scores of quality of life,after adjusting for related confounding factors,pain(P=0.020)and overall health status(P=0.024)are still closely related to MS.3 Survival analysis found that the PFS of the case group was 5.838±0.180 months and the PFS of the control group was 5.989±0.135 months,There was no statistically significant difference in progression time between the two groups(?~2=0.091,P=0.763).The OS in the case group was 13.854±0.339 months and the OS in the control group was 14.261±0.300 months,There was no statistically significant difference in progression time between the two groups(?~2=0.349,P=0.555).4 The COX regression model shows that age(P=0.015)and TNM stage(P<0.001)have an effect on the progression-free survival of lung adenocarcinoma,while MS has no effect on the progression-free survival of lung adenocarcinoma(P=0.051);TNM Staging has an effect on overall survival status(P=0.001),while MS has no effect on overall survival status(P=0.053).Conclusions 1 Obesity,hypertension,hyperglycemia,and hyperlipidemia are typical clinical features of patients with metabolic syndrome and lung adenocarcinoma,and the clinical characteristics of reduced quality of life are mainly manifested in pain symptoms and overall health.2 Whether metabolic syndrome is combined has no significant effect on PFS and OS in patients with lung adenocarcinoma.Figure1;Table17;Reference 182.